Esaxerenone in Patients with Uncontrolled Hypertension Despite Existing Therapy: A Comprehensive Review

Abstract

Esaxerenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA), has emerged as a promising agent for patients with uncontrolled hypertension despite existing antihypertensive therapy. This review synthesizes current scientific evidence and clinical guidelines to assess the efficacy, safety, and practical role of esaxerenone in this challenging patient population. We discuss pathophysiological mechanisms, epidemiologic impact, risk factors, clinical presentations, diagnostic considerations, and the latest therapeutic advances, providing an in-depth perspective for clinicians managing resistant hypertension.

Introduction

Hypertension remains a leading modifiable risk factor for cardiovascular morbidity and mortality worldwide. Despite the availability of multiple antihypertensive drug classes, a significant proportion of patients fail to achieve target blood pressure (BP) levels, a condition termed resistant or uncontrolled hypertension. The emergence of esaxerenone, a potent and selective non-steroidal MRA, has generated substantial interest for its potential to address this therapeutic gap. This review critically appraises the evidence base for esaxerenone in patients with uncontrolled hypertension refractory to standard therapy, emphasizing its clinical utility, pharmacological profile, and integration into current practice.

Epidemiology / Disease Burden

Uncontrolled hypertension affects an estimated 10-20% of all hypertensive patients and is associated with a markedly increased risk of cardiovascular events, chronic kidney disease (CKD), and mortality. Epidemiological data underscore that despite adherence to multidrug regimens, including renin-angiotensin system inhibitors, calcium channel blockers, and diuretics, a substantial subset of patients remain hypertensive. This persistent elevation of BP is particularly prevalent among older adults, patients with comorbid diabetes or CKD, and those of African descent. The public health burden is significant, as uncontrolled hypertension contributes disproportionately to stroke, heart failure, and progressive nephropathy, necessitating novel therapeutic strategies.

Pathophysiology

Resistant hypertension is multifactorial in origin, frequently involving excessive activation of the renin-angiotensin-aldosterone system (RAAS). Aldosterone, acting via mineralocorticoid receptors (MR), promotes sodium retention, vascular inflammation, and fibrosis, leading to persistent BP elevation. Standard MRAs such as spironolactone and eplerenone have demonstrated efficacy in targeting aldosterone-driven pathophysiology but are limited by adverse effects including hyperkalemia and hormonal side effects. Esaxerenone is a highly selective and non-steroidal MRA, conferring potent blockade of MR-mediated pathways with a favorable safety profile, thereby offering mechanistic advantages in the treatment of resistant hypertension.

Risk Factors

Key risk factors for uncontrolled hypertension include non-adherence to therapy, obesity, high dietary sodium intake, excessive alcohol consumption, chronic kidney disease, diabetes mellitus, and secondary causes such as primary aldosteronism, obstructive sleep apnea, and renovascular disease. Genetic predisposition, increased sympathetic activity, and hyperaldosteronism further contribute to treatment resistance. Recognizing these factors is essential for risk stratification and optimizing therapeutic interventions, including the consideration of MR antagonism with agents like esaxerenone.

Clinical Features

Patients with uncontrolled hypertension may be asymptomatic or present with symptoms of end-organ damage, such as headache, visual disturbances, chest pain, dyspnea, or signs of heart failure. Clinical evaluation often reveals persistently elevated BP despite the use of at least three antihypertensive agents of different classes, ideally including a diuretic. Complications such as left ventricular hypertrophy, proteinuria, and retinopathy are common, underscoring the need for aggressive management.

Diagnosis

The diagnosis of uncontrolled hypertension requires confirmation of persistently elevated clinic or ambulatory BP measurements despite optimal doses of at least three antihypertensive agents, including a diuretic. Pseudoresistance due to white coat hypertension, non-adherence, or suboptimal measurement techniques should be excluded. Comprehensive evaluation should include assessment for secondary causes, assessment of end-organ damage, and laboratory testing including renal function and serum potassium. Identification of aldosterone excess is particularly relevant in considering MR antagonist therapy.

Treatment & Management

Management of uncontrolled hypertension mandates a multifaceted approach. Lifestyle modifications remain foundational, encompassing dietary sodium restriction, weight management, exercise, and moderation of alcohol intake. Pharmacologic management typically involves optimizing existing regimens, ensuring adequate dosing, and addressing adherence issues. MRAs represent a key therapeutic class for patients with resistant hypertension. Esaxerenone, as a selective non-steroidal MRA, exerts potent antihypertensive effects by blocking aldosterone-mediated sodium reabsorption and mitigating vascular inflammation. Clinical trials have demonstrated significant BP reductions with esaxerenone in patients uncontrolled on conventional therapy, with a lower incidence of adverse effects compared to steroidal MRAs.

Recent Advances / Emerging Therapies

Esaxerenone has gained attention following robust phase 3 clinical trials, notably the ESAX-HTN and ESAX-DN studies, which demonstrated its efficacy and safety in patients with essential hypertension and those with diabetes and albuminuria. The agent provides sustained BP lowering, favorable effects on albuminuria, and a reduced risk of hyperkalemia relative to older MRAs. Ongoing research is exploring its utility in broader populations, including those with heart failure and advanced CKD. Additionally, the development of novel combination therapies and precision medicine approaches may further enhance the role of esaxerenone in resistant hypertension management.

Guideline Recommendations

Recent hypertension guidelines, including those from the American Heart Association (AHA) and European Society of Cardiology (ESC), endorse the use of MRAs for patients with resistant hypertension, especially when aldosterone excess is suspected. While spironolactone remains the most extensively studied agent, esaxerenone is increasingly recognized for its efficacy and tolerability. Japanese hypertension guidelines have specifically recommended esaxerenone for patients inadequately controlled with standard regimens. Clinicians are advised to monitor renal function and electrolyte status during therapy, with individualized titration based on patient risk profiles.

Conclusion

Esaxerenone represents a significant advancement in the management of uncontrolled hypertension, offering potent and selective MR antagonism with a favorable safety and tolerability profile. Its clinical benefits are substantiated by recent evidence from rigorous clinical trials, supporting its integration into the therapeutic armamentarium for patients refractory to conventional therapy. Ongoing research and evolving guidelines will further define its role and optimize its application in diverse patient populations. For clinicians managing resistant hypertension, esaxerenone provides a valuable option that addresses key pathophysiological mechanisms while minimizing treatment-related risks.